Skip to main content
PMC home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1996 Jul;3(4):399–402. doi: 10.1128/cdli.3.4.399-402.1996

Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a "gold standard"?

S M Callister 1, D A Jobe 1, R F Schell 1, C S Pavia 1, S D Lovrich 1
PMCID: PMC170357  PMID: 8807203

Abstract

The serodiagnosis of early Lyme disease has been plagued with problems of sensitivity and specificity. We found that the flow-cytometric borreliacidal-antibody test had a sensitivity of 72% for the detection of patients with early Lyme disease. By contrast, the sensitivity of the enzyme immunofluorescence assay was 28%. The enhanced sensitivity of the borreliacidal-antibody test was due to the use of Borrelia burgdorferi 50772, which lacks OspA and OspB. When B. burgdorferi 297, which expresses both OspA and OspB, was used, the sensitivity of the borreliacidal-antibody test was 15%. Our results also showed that the borreliacidal-antibody test was specific. No borreliacidal activity was detected in normal sera or in sera from patients with mononucleosis, rheumatoid factor, or syphilis. These results demonstrate that the flow-cytometric borreliacidal-antibody test may be the laboratory "gold standard" for the serodiagnosis of Lyme disease.

Full Text

The Full Text of this article is available as a PDF (221.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguero-Rosenfeld M. E., Nowakowski J., McKenna D. F., Carbonaro C. A., Wormser G. P. Serodiagnosis in early Lyme disease. J Clin Microbiol. 1993 Dec;31(12):3090–3095. doi: 10.1128/jcm.31.12.3090-3095.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Asbrink E., Hovmark A. Early and late cutaneous manifestations in Ixodes-borne borreliosis (erythema migrans borreliosis, Lyme borreliosis). Ann N Y Acad Sci. 1988;539:4–15. doi: 10.1111/j.1749-6632.1988.tb31833.x. [DOI] [PubMed] [Google Scholar]
  3. Aydintug M. K., Gu Y., Philipp M. T. Borrelia burgdorferi antigens that are targeted by antibody-dependent, complement-mediated killing in the rhesus monkey. Infect Immun. 1994 Nov;62(11):4929–4937. doi: 10.1128/iai.62.11.4929-4937.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baranton G., Postic D., Saint Girons I., Boerlin P., Piffaretti J. C., Assous M., Grimont P. A. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis. Int J Syst Bacteriol. 1992 Jul;42(3):378–383. doi: 10.1099/00207713-42-3-378. [DOI] [PubMed] [Google Scholar]
  5. Barbour A. G., Burgdorfer W., Grunwaldt E., Steere A. C. Antibodies of patients with Lyme disease to components of the Ixodes dammini spirochete. J Clin Invest. 1983 Aug;72(2):504–515. doi: 10.1172/JCI110998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Callister S. M., Agger W. A., Schell R. F., Ellingson J. L. Borrelia burgdorferi infection surrounding La Crosse, Wis. J Clin Microbiol. 1988 Dec;26(12):2632–2636. doi: 10.1128/jcm.26.12.2632-2636.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Callister S. M., Schell R. F., Case K. L., Lovrich S. D., Day S. P. Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test. J Infect Dis. 1993 Jan;167(1):158–164. doi: 10.1093/infdis/167.1.158. [DOI] [PubMed] [Google Scholar]
  8. Callister S. M., Schell R. F., Lim L. C., Jobe D. A., Case K. L., Bryant G. L., Molling P. E. Detection of borreliacidal antibodies by flow cytometry. An accurate, highly specific serodiagnostic test for Lyme disease. Arch Intern Med. 1994 Jul 25;154(14):1625–1632. [PubMed] [Google Scholar]
  9. Callister S. M., Schell R. F., Lovrich S. D. Lyme disease assay which detects killed Borrelia burgdorferi. J Clin Microbiol. 1991 Sep;29(9):1773–1776. doi: 10.1128/jcm.29.9.1773-1776.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Coleman J. L., Rogers R. C., Benach J. L. Selection of an escape variant of Borrelia burgdorferi by use of bactericidal monoclonal antibodies to OspB. Infect Immun. 1992 Aug;60(8):3098–3104. doi: 10.1128/iai.60.8.3098-3104.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Creson J. R., Lim L. C., Glowacki N. J., Callister S. M., Schell R. F. Detection of anti-Borrelia burgdorferi antibody responses with the borreliacidal antibody test, indirect fluorescent-antibody assay performed by flow cytometry, and western immunoblotting. Clin Diagn Lab Immunol. 1996 Mar;3(2):184–190. doi: 10.1128/cdli.3.2.184-190.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dattwyler R. J., Halperin J. J., Volkman D. J., Luft B. J. Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin. Lancet. 1988 May 28;1(8596):1191–1194. doi: 10.1016/s0140-6736(88)92011-9. [DOI] [PubMed] [Google Scholar]
  13. Dressler F., Whalen J. A., Reinhardt B. N., Steere A. C. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis. 1993 Feb;167(2):392–400. doi: 10.1093/infdis/167.2.392. [DOI] [PubMed] [Google Scholar]
  14. Engstrom S. M., Shoop E., Johnson R. C. Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. J Clin Microbiol. 1995 Feb;33(2):419–427. doi: 10.1128/jcm.33.2.419-427.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fikrig E., Bockenstedt L. K., Barthold S. W., Chen M., Tao H., Ali-Salaam P., Telford S. R., Flavell R. A. Sera from patients with chronic Lyme disease protect mice from Lyme borreliosis. J Infect Dis. 1994 Mar;169(3):568–574. doi: 10.1093/infdis/169.3.568. [DOI] [PubMed] [Google Scholar]
  16. Kalish R. A., Leong J. M., Steere A. C. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun. 1993 Jul;61(7):2774–2779. doi: 10.1128/iai.61.7.2774-2779.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kalish R. A., Leong J. M., Steere A. C. Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease. Infect Immun. 1995 Jun;63(6):2228–2235. doi: 10.1128/iai.63.6.2228-2235.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lightfoot R. W., Jr, Luft B. J., Rahn D. W., Steere A. C., Sigal L. H., Zoschke D. C., Gardner P., Britton M. C., Kaufman R. L. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis. Ann Intern Med. 1993 Sep 15;119(6):503–509. doi: 10.7326/0003-4819-119-6-199309150-00010. [DOI] [PubMed] [Google Scholar]
  19. Ma J., Gingrich-Baker C., Franchi P. M., Bulger P., Coughlin R. T. Molecular analysis of neutralizing epitopes on outer surface proteins A and B of Borrelia burgdorferi. Infect Immun. 1995 Jun;63(6):2221–2227. doi: 10.1128/iai.63.6.2221-2227.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. McAlister H. F., Klementowicz P. T., Andrews C., Fisher J. D., Feld M., Furman S. Lyme carditis: an important cause of reversible heart block. Ann Intern Med. 1989 Mar 1;110(5):339–345. doi: 10.7326/0003-4819-110-5-339. [DOI] [PubMed] [Google Scholar]
  21. Moskophidis M., Luther B. Monoclonal antibodies with in vitro borreliacidal activities define the outer surface proteins A and B of Borrelia burgdorferi. Zentralbl Bakteriol. 1993 Jun;279(2):201–213. doi: 10.1016/s0934-8840(11)80398-1. [DOI] [PubMed] [Google Scholar]
  22. Nguyen T. P., Lam T. T., Barthold S. W., Telford S. R., 3rd, Flavell R. A., Fikrig E. Partial destruction of Borrelia burgdorferi within ticks that engorged on OspE- or OspF-immunized mice. Infect Immun. 1994 May;62(5):2079–2084. doi: 10.1128/iai.62.5.2079-2084.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pachner A. R., Steere A. C. The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis. Neurology. 1985 Jan;35(1):47–53. doi: 10.1212/wnl.35.1.47. [DOI] [PubMed] [Google Scholar]
  24. Padula S. J., Sampieri A., Dias F., Szczepanski A., Ryan R. W. Molecular characterization and expression of p23 (OspC) from a North American strain of Borrelia burgdorferi. Infect Immun. 1993 Dec;61(12):5097–5105. doi: 10.1128/iai.61.12.5097-5105.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Preac-Mursic V., Weber K., Pfister H. W., Wilske B., Gross B., Baumann A., Prokop J. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection. 1989 Nov-Dec;17(6):355–359. doi: 10.1007/BF01645543. [DOI] [PubMed] [Google Scholar]
  26. Preac-Mursic V., Wilske B., Patsouris E., Jauris S., Will G., Soutschek E., Rainhardt S., Lehnert G., Klockmann U., Mehraein P. Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection. Infection. 1992 Nov-Dec;20(6):342–349. doi: 10.1007/BF01710681. [DOI] [PubMed] [Google Scholar]
  27. Probert W. S., LeFebvre R. B. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect Immun. 1994 May;62(5):1920–1926. doi: 10.1128/iai.62.5.1920-1926.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sadziene A., Jonsson M., Bergström S., Bright R. K., Kennedy R. C., Barbour A. G. A bactericidal antibody to Borrelia burgdorferi is directed against a variable region of the OspB protein. Infect Immun. 1994 May;62(5):2037–2045. doi: 10.1128/iai.62.5.2037-2045.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sadziene A., Thompson P. A., Barbour A. G. In vitro inhibition of Borrelia burgdorferi growth by antibodies. J Infect Dis. 1993 Jan;167(1):165–172. doi: 10.1093/infdis/167.1.165. [DOI] [PubMed] [Google Scholar]
  30. Sambri V., Armati S., Cevenini R. Animal and human antibodies reactive with the outer surface protein A and B of Borrelia burgdorferi are borreliacidal, in vitro, in the presence of complement. FEMS Immunol Med Microbiol. 1993 Jun;7(1):67–71. doi: 10.1111/j.1574-695X.1993.tb00383.x. [DOI] [PubMed] [Google Scholar]
  31. Schutzer S. E., Coyle P. K., Dunn J. J., Luft B. J., Brunner M. Early and specific antibody response to OspA in Lyme Disease. J Clin Invest. 1994 Jul;94(1):454–457. doi: 10.1172/JCI117346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Schwan T. G., Piesman J., Golde W. T., Dolan M. C., Rosa P. A. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2909–2913. doi: 10.1073/pnas.92.7.2909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Scriba M., Ebrahim J. S., Schlott T., Eiffert H. The 39-kilodalton protein of Borrelia burgdorferi: a target for bactericidal human monoclonal antibodies. Infect Immun. 1993 Oct;61(10):4523–4526. doi: 10.1128/iai.61.10.4523-4526.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Steere A. C., Bartenhagen N. H., Craft J. E., Hutchinson G. J., Newman J. H., Rahn D. W., Sigal L. H., Spieler P. N., Stenn K. S., Malawista S. E. The early clinical manifestations of Lyme disease. Ann Intern Med. 1983 Jul;99(1):76–82. doi: 10.7326/0003-4819-99-1-76. [DOI] [PubMed] [Google Scholar]
  35. Steere A. C., Schoen R. T., Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med. 1987 Nov;107(5):725–731. doi: 10.7326/0003-4819-107-5-725. [DOI] [PubMed] [Google Scholar]
  36. Steere A. C., Taylor E., McHugh G. L., Logigian E. L. The overdiagnosis of Lyme disease. JAMA. 1993 Apr 14;269(14):1812–1816. [PubMed] [Google Scholar]
  37. Stevenson B., Schwan T. G., Rosa P. A. Temperature-related differential expression of antigens in the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun. 1995 Nov;63(11):4535–4539. doi: 10.1128/iai.63.11.4535-4539.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES